Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma

Sato, Miki Takenaka; Ida, Ayuki; Kanda, Yuki; Takano, Kaori; Ohbayashi, Masayuki; Kohyama, Noriko; Morita, Jun; Fuji, Kohzo; Sasaki, Haruaki; Ogawa, Yoshio; Kogo, Mari

doi:10.1186/s12885-022-10316-w

BMC Cancer

Article metrics
Last updated: Wed, 17 Apr 2024 10:16:11 Z

Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma

Access & Citations

1114

Article Accesses
0

Web of Science
2

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com